Sadeghi H M, Innamorati G, Birnbaumer M
Department of Anesthesiology and Molecular Biology Institute, University of California Los Angeles School of Medicine, 90095, USA.
Mol Endocrinol. 1997 Jun;11(6):706-13. doi: 10.1210/mend.11.6.9919.
Function and biochemical properties of the V2 vasopressin receptor (V2R) mutant R337ter, identified in patients suffering from X-linked recessive nephrogenic diabetes insipidus, were investigated by expression in COS.M6 or HEK293 cells. Binding assays and measurements of adenylyl cyclase activity failed to detect function for the truncated receptor, although metabolic labeling demonstrated normal levels of protein synthesis. ELISA assays performed on cells expressing the receptors tagged at the amino terminus with the HA epitope failed to detect V2R R337ter on the plasma membrane. Treatment with endoglycosidase H revealed that the receptor was present only as a precursor form because the mature R337ter V2R, resistant to endoglycosidase H treatment, was not detected. The precursor of V2R-R337ter had a longer half-life than that of the wild type V2R, suggesting that arrested maturation may slow the degradation of the precursor. Unrelated experiments had demonstrated that V2R-G345ter, containing eight additional amino acids, was expressed on the plasma membrane and functioned normally. Receptor truncations longer than 337ter revealed that four of the eight amino acids identified initially provided the minimum length required for the protein to acquire cell surface expression. This was shown by the production of mature receptor (V2R-341ter) detectable in SDS-PAGE, which mediated arginine vasopressin stimulation of adenylyl cyclase activity and bound ligand. In addition, the identity of amino acid 340 was found to play a role in this phenomenon. In conclusion, these data demonstrate that the V2R R337ter is nonfunctional because it does not reach the plasma membrane and that the minimal protein length required for translocation of the V2R to the cell surface is sufficient to confer function to the receptor protein. They also suggest the existence of a protein quality control in the endoplasmic reticulum independent of glycosylation.
对在患有X连锁隐性肾性尿崩症的患者中鉴定出的V2血管加压素受体(V2R)突变体R337ter的功能和生化特性,通过在COS.M6或HEK293细胞中表达进行了研究。尽管代谢标记显示蛋白质合成水平正常,但结合试验和腺苷酸环化酶活性测量未能检测到截短受体的功能。对用HA表位在氨基末端标记的受体进行表达的细胞进行ELISA试验,未能在质膜上检测到V2R R337ter。用内切糖苷酶H处理表明,该受体仅以前体形式存在,因为未检测到对内切糖苷酶H处理有抗性的成熟R337ter V2R。V2R-R337ter的前体半衰期比野生型V2R的长,这表明成熟停滞可能会减缓前体的降解。无关实验表明,含有另外八个氨基酸的V2R-G345ter在质膜上表达且功能正常。比337ter更长的受体截短表明,最初鉴定出的八个氨基酸中的四个提供了蛋白质获得细胞表面表达所需的最小长度。这通过在SDS-PAGE中可检测到的成熟受体(V2R-341ter)的产生得到证明,该受体介导精氨酸血管加压素对腺苷酸环化酶活性的刺激并结合配体。此外,发现氨基酸340的身份在这一现象中起作用。总之,这些数据表明V2R R337ter无功能,因为它未到达质膜,并且V2R转运到细胞表面所需的最小蛋白质长度足以赋予受体蛋白功能。它们还表明在内质网中存在独立于糖基化的蛋白质质量控制。